Dynavax Technologies Corp. (NASDAQ: DVAX) closed the day trading at $12.17 down -3.72% from the previous closing price of $12.64. In other words, the price has decreased by -$0.47 from its previous closing price. On the day, 2737434 shares were traded. DVAX stock price reached its highest trading level at $12.70 during the session, while it also had its lowest trading level at $12.03.
Ratios:
For a better understanding of DVAX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.14 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.48. For the most recent quarter (mrq), Quick Ratio is recorded 12.96 and its Current Ratio is at 13.81. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.41.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on February 01, 2024, initiated with a Neutral rating and assigned the stock a target price of $20.
On September 27, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $22.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 01 ’24 when Burgess Justin sold 20,526 shares for $12.78 per share. The transaction valued at 262,322 led to the insider holds 0 shares of the business.
Janssen Robert sold 1,500 shares of DVAX for $22,500 on Jan 04 ’24. The SVP and CMO now owns 49,925 shares after completing the transaction at $15.00 per share. On Jan 02 ’24, another insider, Novack David F, who serves as the President & COO of the company, sold 9,000 shares for $14.45 each. As a result, the insider received 130,050 and left with 3,187 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DVAX now has a Market Capitalization of 1.59B and an Enterprise Value of 1.11B. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.84 while its Price-to-Book (P/B) ratio in mrq is 2.53. Its current Enterprise Value per Revenue stands at 4.76 whereas that against EBITDA is 114.37.
Stock Price History:
Over the past 52 weeks, DVAX has reached a high of $15.15, while it has fallen to a 52-week low of $9.42. The 50-Day Moving Average of the stock is 13.23, while the 200-Day Moving Average is calculated to be 13.59.
Shares Statistics:
Over the past 3-months, DVAX traded about 1.94M shares per day on average, while over the past 10 days, DVAX traded about 1.68M shares per day. A total of 130.62M shares are outstanding, with a floating share count of 130.22M. Insiders hold about 0.30% of the company’s shares, while institutions hold 96.85% stake in the company. Shares short for DVAX as of Feb 29, 2024 were 16.37M with a Short Ratio of 8.45, compared to 14.33M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 12.53% and a Short% of Float of 15.25%.
Earnings Estimates
Current recommendations for the stock of the company come from 4 analysts. On average, analysts expect EPS of -$0.02 for the current quarter, with a high estimate of $0.03 and a low estimate of -$0.06, while EPS last year was -$0.19. The consensus estimate for the next quarter is $0.09, with high estimates of $0.12 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.37 and $0.15 for the fiscal current year, implying an average EPS of $0.26. EPS for the following year is $0.51, with 5 analysts recommending between $0.74 and $0.29.
Revenue Estimates
4 analysts predict $55.67M in revenue for the current quarter. It ranges from a high estimate of $61.24M to a low estimate of $50.71M. As of the current estimate, Dynavax Technologies Corp.’s year-ago sales were $38.59M, an estimated increase of 44.30% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $78.37M, an increase of 62.00% over than the figure of $44.30% in the same quarter last year. There is a high estimate of $80M for the next quarter, whereas the lowest estimate is $76.33M.
A total of 5 analysts have provided revenue estimates for DVAX’s current fiscal year. The highest revenue estimate was $301.07M, while the lowest revenue estimate was $273.1M, resulting in an average revenue estimate of $287.96M. In the same quarter a year ago, actual revenue was $232.28M, up 24.00% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $347.37M in the next fiscal year. The high estimate is $376.34M and the low estimate is $314.02M. The average revenue growth estimate for next year is up 20.60% from the average revenue estimate for this year.
